(Hacettepe Üniversitesi, Tıp Fakültesi, Pediatrik Alerji Anabilim Dalı, Ankara, Türkiye)
Bülent Enis ŞEKEREL
(Hacettepe Üniversitesi, Tıp Fakültesi, Pediatrik Alerji Anabilim Dalı, Ankara, Türkiye)
Ümit Murat ŞAHINER
(Hacettepe Üniversitesi, Tıp Fakültesi, Pediatrik Alerji Anabilim Dalı, Ankara, Türkiye)
Yıl: 2021Cilt: 51Sayı: 5ISSN: 1300-0144 / 1303-6165Sayfa Aralığı: 2233 - 2242İngilizce

0 0
Allergic reactions against Covıd-19 vaccines
Abstract: Coronavirus Disease 2019 (COVID-19) affected the whole world in a short time. One of the most influential public health initiatives modern medicine has to offer, the vaccine has become even more important as the COVID-19 pandemic continues to worsen worldwide. Many vaccine trials were launched during the COVID-19 pandemic, and these vaccines were widely used around the world, offering realistic hope for ending the pandemic. Allergic reactions to vaccines were reported shortly after their approval. These reactions, in general, are rare, but, in some circumstances, they can be serious. Allergy to vaccines can occur because of either the active vaccine component or vaccine ingredients. The spectrum of the reactions may be just a local hypersensitiviy reaction or may be as severe as an anaphylaxis, which is an acute severe, life-threatening systemic hypersensitive reaction, and it requires quick intervention. If an allergy is suspected, a correct examination followed by algorithms is important for true diagnosis, treatment, and decision regarding revaccination. Patients who experience an allergic reaction with the first dose of covid 19 vaccine should be directed to the allergyimmunologist, and the evaluation of at-risk patients should be individualized. Finally, we should point out that the benefits of current COVID-19 vaccines go far beyond the side effects, and that the vaccine is the most important way to recover from the pandemic. Key words: COVID-19, vaccine, allergy, hypersensitiviy, polyethylene glycol
DergiAraştırma MakalesiErişime Açık
  • 1. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Molecular Medicine. 2014; 6 (6): 708-720. doi: 10.1002/emmm.201403876
  • 2. Whitney CG, Zhou F, Singleton J, Schuchat A. Benefits from immunization during the vaccines for children program era— United States, 1994–2013. MMWR Morbidity and Mortality Weekly Report. 2014; 63 (16): 352
  • 3. McNeil MM, Weintraub ES, Duffy J, Sukumaran L, Jacobsen SJ et al. Risk of anaphylaxis after vaccination in children and adults. Journal of Allergy and Clinical Immunology. 2016; 137 (3): 868-878. doi: 10.1016/j.jaci.2015.07.048
  • 4. Kelso JM. Anaphylactic reactions to novel mRNA SARSCoV-2/COVID-19 vaccines. Vaccine. 2021; 39 (6): 865. doi: 10.1016/j.vaccine.2020.12.084
  • 5. Murphy KR, Patel NC, Ein D, Hudelson M, Kodoth S et al. Insights from American College of Allergy, Asthma, and Immunology COVID-19 Vaccine Task Force: Allergic Reactions to mRNA SARS-CoV-2 Vaccines: Allergic Reactions to mRNA SARS-CoV-2 Vaccines. Annals of Allergy, Asthma & Immunology. 2021. doi: 10.1016/j.anai.2021.01.017
  • 6. COVID C, Team R. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine—United States, December 14–23, 2020. Morbidity and Mortality Weekly Report. 2021; 70 (2): 46. doi: 10.15585/ mmwr.mm7002e1
  • 7. COVID C, Team R. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine—United States, December 21, 2020–January 10, 2021. Morbidity and Mortality Weekly Report. 2021; 70 (4): 125. doi: 10.15585/mmwr.mm7004e1
  • 8. Echeverría-Zudaire LA, Ortigosa-del Castillo L, AlonsoLebrero E, Álvarez-García FJ, Cortés-Álvarez N et al. Consensus document on the approach to children with allergic reactions after vaccination or allergy to vaccine components. Allergologia et Immunopathologia. 2015; 43 (3): 304-325. doi: 10.1016/j.aller.2015.01.004
  • 9. Simons FER, Ebisawa M, Sanchez-Borges M, Thong BY, Worm M et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organization Journal. 2015; 8: 32. doi: 10.1186/s40413-015- 0080-1
  • 10. McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. Journal of Allergy and Clinical Immunology. 2018; 141 (2): 463-472. doi: 10.1016/j.jaci.2017.12.971
  • 11. Stone Jr CA, Rukasin CR, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. British Journal of Clinical Pharmacology. 2019; 85 (12): 2694-2706. doi: 10.1111/bcp.14112
  • 12. da Silva EZM, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. Journal of Histochemistry & Cytochemistry. 2014; 62 (10): 698-738. doi: 10.1369/0022155414545334
  • 13. Porebski G, Kwiecien K, Pawica M, Kwitniewski M. Masrelated G protein-coupled receptor-X2 (MRGPRX2) in drug hypersensitivity reactions. Frontiers in Immunology. 2018; 9: 3027. doi: 10.3389/fimmu.2018.03027
  • 14. Spoerl D, Nigolian H, Czarnetzki C, Harr T. Reclassifying anaphylaxis to neuromuscular blocking agents based on the presumed patho-mechanism: IgE-mediated, pharmacological adverse reaction or “innate hypersensitivity”? International Journal of Molecular Sciences. 2017; 18 (6): 1223. doi: 10.3390/ ijms18061223
  • 15. Wood RA, Berger M, Dreskin SC, Setse R, Engler RJ et al. An algorithm for treatment of patients with hypersensitivity reactions after vaccines. Pediatrics. 2008; 122 (3): e771-e777. doi: 10.1542/peds.2008-1002
  • 16. Johansson S, Hourihane JB, Bousquet J, Bruijnzeel-Koomen C, Dreborg S et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy. 2001; 56 (9): 813-824. doi: 10.1034/j.1398-9995.2001. t01-1-00001.x
  • 17. Kelso JM, Greenhawt MJ, Li JT, Nicklas RA, Bernstein DI et al. Adverse reactions to vaccines practice parameter 2012 update. Journal of Allergy and Clinical Immunology. 2012; 130 (1): 25- 43. doi: 10.1016/j.jaci.2012.04.003
  • 18. Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organization Journal. 2016; 9 (1): 32. doi: 10.1186/s40413-016-0120-5
  • 19. Muraro A, Roberts G, Worm M, Bilò M, Brockow K et al. Anaphylaxis: guidelines from the E uropean A cademy of A llergy and C linical I mmunology. Allergy. 2014; 69 (8): 1026- 1045. doi: 10.1111/all.12437
  • 20. Johansson S, Bieber T, Dahl R, Friedmann PS, Lanier BQ et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy and Clinical Immunology. 2004; 113 (5): 832-836. doi: 10.1016/j. jaci.2003.12.591
  • 21. Anaphylaxis; Turkish National Guideline 2018; Volume: 16, Supplement: 1, 2018, editor; Orhan F. Asthma Allergy Immunology.
  • 22. Sampson HA, Muñoz-Furlong A, Campbell RL, Adkinson Jr NF, Bock SA et al. Second symposium on the definition and management of anaphylaxis: summary report—Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. Journal of Allergy and Clinical Immunology. 2006; 117 (2): 391-397. doi: 10.1016/j.jaci.2005.12.1303
  • 23. Bohlke K, Davis RL, DeStefano F, Marcy SM, Braun MM et al. Epidemiology of anaphylaxis among children and adolescents enrolled in a health maintenance organization. Journal of Allergy and Clinical Immunology. 2004; 113 (3): 536-542. doi: 10.1016/j.jaci.2003.11.033
  • 24. Brown SG. Clinical features and severity grading of anaphylaxis. Journal of Allergy and Clinical Immunology. 2004; 114 (2): 371-376. doi: 10.1016/j.jaci.2004.04.029
  • 25. Vanlander A, Hoppenbrouwers K. Anaphylaxis after vaccination of children: review of literature and recommendations for vaccination in child and school health services in Belgium. Vaccine. 2014; 32 (26): 3147-3154. doi: 10.1016/j.vaccine.2014.03.096
  • 26. Control CfD, Prevention. Syncope after vaccination--United States, January 2005-July 2007. MMWR Morbidity and Mortality Weekly Report. 2008; 57 (17): 457-460
  • 27. Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Current Opinion in Allergy and Clinical Immunology. 2005; 5 (4): 359-364. doi: 10.1097/01. all.0000174158.78626.35
  • 28. Caubet J-C, Ponvert C. Vaccine Allergy. Immunology and Allergy Clinics. 2014; 34 (3): 597-613. doi: 10.1016/j. iac.2014.04.004
  • 29. Bergfors E, Trollfors B. Sixty-four children with persistent itching nodules and contact allergy to aluminium after vaccination with aluminium-adsorbed vaccines—prognosis and outcome after booster vaccination. European Journal of Pediatrics. 2013; 172 (2): 171-177. doi: 10.1007/s00431-012- 1841-2
  • 30. Nilsson L, Brockow K, Alm J, Cardona V, Caubet JC et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatric Allergy and Immunology. 2017; 28 (7): 628- 640. doi: 10.1111/pai.12762
  • 31. Jackson LA, Starkovich P, Dunstan M, Yu O, Nelson J et al. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination. Pediatrics. 2008; 121 (3): e646-e652. doi: 10.1542/peds.2007-1653
  • 32. Jackson LA, Peterson D, Nelson JC, Marcy SM, Naleway AL et al. Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics. 2013; 131 (2): 283-289. doi: 10.1542/peds.2012-2617
  • 33. for Immunization NC. General recommendations on immunization---recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports. 2011; 60 (2): 1-64
  • 34. Dreskin SC, Halsey NA, Kelso JM, Wood RA, Hummell DS et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organization Journal. 2016; 9 (1): 1-21. doi: 10.1186/s40413-016-0120-5
  • 35. Turner PJ, Ansotegui IJ, Campbell DE, Cardona V, Ebisawa M et al. COVID-19 Vaccine-associated anaphylaxis: a statement of the world allergy organization anaphylaxis committee. World Allergy Organization Journal. 2021: 100517. doi: 10.1016/j.waojou.2021.100517
  • 36. Banerji A, Wickner PG, Saff R, Stone Jr CA, Robinson LB et al. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Approach. The Journal of Allergy and Clinical Immunology: In Practice. 2020. doi: 10.1016/j.jaip.2020.12.047
  • 37. Kleine-Tebbe J, Klimek L, Hamelmann E, Pfaar O, Taube C et al. Severe allergic reactions to the COVID-19 vaccine– statement and practical consequences. Allergologie Select. 2021; 5: 26. doi: 10.5414/ALX02215E
  • 38. Sellaturay P, Nasser S, Ewan P. Polyethylene Glycol–Induced Systemic Allergic Reactions (Anaphylaxis). The Journal of Allergy and Clinical Immunology: In Practice. 2021; 9 (2): 670- 675. doi: 10.1016/j.jaip.2020.09.029
  • 39. Bruusgaard-Mouritsen MA, Johansen JD, Garvey LH. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients. Clinical & Experimental Allergy. doi: 10.1111/cea.13822
  • 40. Wenande E, Garvey L. Immediate-type hypersensitivity to polyethylene glycols: a review. Clinical & Experimental Allergy. 2016; 46 (7): 907-922. doi: 10.1111/cea.12760
  • 41. Zhou Z-H, Stone Jr CA, Jakubovic B, Phillips EJ, Sussman G et al. Anti-PEG IgE in anaphylaxis associated with polyethylene glycol. The Journal of Allergy and Clinical Immunology: In Practice. 2020. doi: 10.1016/j.jaip.2020.11.011
  • 42. Stone Jr CA, Liu Y, Relling MV, Krantz MS, Pratt AL et al. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. The Journal of Allergy and Clinical Immunology: In Practice. 2019; 7 (5): 1533-1540. e8. doi: 10.1016/j.jaip.2018.12.003
  • 43. Fruijtier-Pölloth C. Safety assessment on polyethylene glycols (PEGs) and their derivatives as used in cosmetic products. Toxicology. 2005; 214 (1-2): 1-38. doi: 10.1016/j. tox.2005.06.001
  • 44. Sahiner UM, Yavuz ST, Gökce M, Buyuktiryaki B, Altan I et al. Anaphylactic reaction to polyethylene-glycol conjugatedasparaginase: Premedication and desensitization may not be sufficient. Pediatrics International. 2013; 55 (4): 531-533. doi: 10.1111/ped.12131
  • 45. Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS et al. Hemodynamic changes induced by liposomes and liposomeencapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation. 1999; 99 (17): 2302-2309. doi: 10.1161/01. cir.99.17.2302
  • 46. Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A et al. PEGylated liposomes: immunological responses. Science and Technology of Advanced Materials. 2019; 20 (1): 710-724. doi: 10.1080/14686996.2019.1627174
  • 47. Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Annals of Allergy, Asthma & Immunology. 2005; 95 (6): 593-599. doi: 10.1016/S1081-1206(10)61024-1
  • 48. Hawe A, Filipe V, Jiskoot W. Fluorescent molecular rotors as dyes to characterize polysorbate-containing IgG formulations. Pharmaceutical Research. 2010; 27 (2): 314-326. doi: 10.1007/ s11095-009-0020-2
  • 49. Cabanillas B, Akdis C, Novak N. Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol? : Wiley Online Library; 2020. doi: 10.1111/all.14711
  • 50. Sokolowska M, Eiwegger T, Ollert M, Torres MJ, Barber D et al. EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy. doi: 10.1111/all.14739
  • 51. Tanno LK, Gonzalez-Estrada A, Olivieri B, Caminati M. Asthma and anaphylaxis. Current Opinion in Allergy and Clinical Immunology. 2019; 19 (5): 447-455. doi: 10.1097/ ACI.0000000000000566
  • 52. Shaker MS, Wallace DV, Golden DB, Oppenheimer J, Bernstein JA et al. Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis. Journal of Allergy and Clinical Immunology. 2020; 145 (4): 1082-1123. doi: 10.1016/j.jaci.2020.01.017
  • 53. Perel P, Roberts I. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database of Systematic Reviews. 2012 (6). doi: 10.1002/14651858. CD000567.pub5
  • 54. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Rivas MF et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organization Journal. 2020; 13 (10): 100472. doi: 10.1016/j.waojou.2020.100472
  • 55. Pumphrey R. Lessons for management of anaphylaxis from a study of fatal reactions. Clinical and Experimental Allergy. 2000; 30 (8): 1144-1150. doi: 10.1046/j.1365-2222.2000.00864.x
  • 56. Simons FER, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK et al. World allergy organization guidelines for the assessment and management of anaphylaxis. World Allergy Organization Journal. 2011; 4 (2): 13-37. doi: 10.1097/ WOX.0b013e318211496c
  • 57. Michelson KA, Monuteaux MC, Neuman MI. Glucocorticoids and hospital length of stay for children with anaphylaxis: a retrospective study. The Journal of Pediatrics. 2015; 167 (3): 719-724. e3. doi: 10.1016/j.jpeds.2015.05.033
  • 58. Alqurashi W, Ellis AK. Do corticosteroids prevent biphasic anaphylaxis? The Journal of Allergy and Clinical Immunology: In Practice. 2017; 5 (5): 1194-1205. doi: 10.1016/j. jaip.2017.05.022
  • 59. Thomas M, Crawford I. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emergency Medicine Journal. 2005; 22 (4): 272-273. doi: 10.1136/ emj.2005.023507

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © 2019 Tüm Hakları Saklıdır.